Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 8, 2021updated 07 Jan 2022 6:43am

Neurocrine’s valbenazine lowers chorea severity in Huntington disease trial

In the trial, adverse events due to valbenazine treatment were in line with the previously reported safety profile. 

Neurocrine Biosciences has reported that the Phase III KINECT-HD clinical trial of its valbenazine met the primary goal of decreasing chorea severity in adults with Huntington disease (HD), a hereditary neurodegenerative disorder.

A selective inhibitor of vesicular monoamine transporter 2 (VMAT2), valbenazine is being examined as a once-daily therapy for HD-linked chorea.

The double-blind, randomised, placebo-controlled trial analysed the efficacy of a once-a-day dose of valbenazine to reduce chorea and its safety and tolerability in people with HD.

It enrolled a total of 128 adult subjects aged 18 to 75 years with motor manifest HD and have substantial symptoms of chorea.

A cardinal motor feature in HD, chorea was assessed by variation in the Unified Huntington’s Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score to the average score from baseline at weeks ten and 12.

Findings showed that valbenazine offered statistically significant improvement in chorea, with a mean decline of 3.2 units in the TMC score.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In addition, valbenazine showed a statistically significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response Status, the secondary goals of the trial.

Treatment-emergent side effects of valbenazine in the trial were in line with the already reported safety profile.

Furthermore, no cases of suicidal behaviour or deterioration of suicidal ideation were noted in subjects who received valbenazine.

KINECT-HD2, another open-label trial of the therapy, is currently dosing subjects. This study will assess the long-term safety and tolerability of valbenazine to treat HD-associated chorea.

Neurocrine Biosciences chief medical officer Eiry Roberts said: “The positive results of the KINECT-HD study move us closer to bringing valbenazine as a potential treatment option to patients in the US living with chorea, one of the most common symptoms of Huntington disease.

“We will review the complete data and begin preparing a supplemental new drug application (sNDA) for submission to the US Food and Drug Administration next year.”

In June 2020, Neurocrine and Takeda Pharmaceutical partnered to develop and market therapeutic compounds in the psychiatry pipeline.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU